RT Journal Article
A1 Chang, Yuh-Shin
A1 Weng, Shih-Feng
A1 Chang, Chun
A1 Wang, Jhi-Joung
A1 Wang, Jiu-Yao
A1 Jan, Ren-Long
T1 Associations Between Topical Ophthalmic Corticosteroids and Central Serous Chorioretinopathy: A Taiwanese Population-Based Study
JF Investigative Ophthalmology & Visual Science
JO Invest. Ophthalmol. Vis. Sci.
YR 2015
DO 10.1167/iovs.14-16360
VO 56
IS 6
SP 4083
OP 4089
SN 1552-5783
AB    To investigate the association between central serous chorioretinopathy (CSCR) and topical ophthalmic corticosteroid use.    Data were collected from the Longitudinal Health Insurance Database 2000, containing randomly selected medical claim data from 23 million residents in Taiwan. The study cohort comprised all patients diagnosed with CSCR between January 2001 and December 2010 (n = 2921) with a control group of patients (n = 17,526) matched to study patients according to age, sex, geographic region, and date of index medical care. Demographic characteristics, comorbidities, and corticosteroid use (topical ophthalmic, oral, nasal spray, injected, and inhaled) within 1 year before CSCR diagnosis were examined using univariate logistic regression. Student's t-test was used for continuous variables. Adjusted logistic regression was used to compare the odds ratio (OR) of the prognosis of CSCR patients with that of controls.    In CSCR patients, we observed an increased prevalence of topical ophthalmic corticosteroid use (OR 6.328, 95% confidence interval [CI] 5.786–6.921, P < 0.0001). After adjusting for age, sex, geographic location of the patient's residence, hypertension, diabetes mellitus, hyperlipidemia, chronic renal disease, peptic ulcer, psychiatric disease, allergic respiratory disease, coronary artery disease, and corticosteroid use, conditional logistic regression analysis showed that CSCR patients were more likely to have used topical ophthalmic corticosteroids recently than the controls (OR 6.036, 95% CI 5.512–6.610, P < 0.0001).    Results strongly support an association between recent topical ophthalmic corticosteroid use and CSCR. Thus, patients who require ophthalmic corticosteroids should be advised of the associated risk of developing CSCR.  
RD 2/28/2021
UL https://doi.org/10.1167/iovs.14-16360